Previous 10 | Next 10 |
Cerecor (CERC) has dosed its first patient in a Phase 1b clinical trial of CERC-007, a fully human anti-IL-18 monoclonal antibody (mAb) being developed for patients with relapsed or refractory multiple myeloma ((MM)).The study will determine the recommended Phase 2 dose, safety and preliminar...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that it has dosed its first patient ...
The FDA signs off Cerecor's (CERC) Investigational New Drug Application for CERC-007 to treat relapsed or refractory multiple myeloma. The first study will be a U.S. multicenter Phase 1b trial, with initial data is expected in Q1 of 2021.The planned 30-patient study will e...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Ap...
China HGS Real Estate (HGSH) +164%.Hexindai (HX) +32%.Sutro Biopharma (STRO) +25% as ovarian cancer drug study offers encouraging interim data.Domo (DOMO) +23% on Q3 results.CIIG Merger (CIIC) +22%.Sigma Labs (SGLB) +20%.Collective Growth Corporation (CGRO) +18%.Foresight Autonomous...
The FDA has signed-off Investigational New Drug Application for Cerecor's (CERC) CERC-803 for the treatment of Leukocyte Adhesion Deficiency Type II (LAD II), an extremely rare congenital disorder due to mutations in the SLC35C1 gene, and characterized by recurrent infections, persistent leuk...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administ...
Cerecor ([[CERC]] +3.7%) has collaborated with The Frontiers in Congenital Disorders of Glycosylation Consortium on a prospective pivotal trial evaluating the safety and efficacy of CERC-801 in patients suffering from Phosphoglucomutase-1 deficiency related congenital disorders of glycosylati...
ROCKVILLE, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced a collaboration with The Frontiers in Congenital Disor...
Cerecor (CERC): Q3 GAAP EPS of -$0.16 misses by $0.06.Revenue of $1.11M (-49.5% Y/Y) misses by $0.39M.Press Release For further details see: Cerecor EPS misses by $0.06, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Cerecor Inc. Company Name:
CERC Stock Symbol:
NASDAQ Market:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at...